ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

by Oryzon Genomics

Oryzon Genomics announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune...

Read more

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Small Cell Lung Cancer

by Oryzon Genomics

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s clinical stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer (...

Read more

ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients

by Oryzon Genomics

Oryzon Genomics has announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) for iadademstat is now approv...

Read more

ORYZON to hold multiple corporate activities in January

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents ...

Read more

ORYZON publishes paper in ACS Pharmacology & Translational Science supporting best-in-class performance of iadademstat in Oncology

by Oryzon Genomics

The manuscript, entitled "Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology”, compares iadademstat with four LSD1 inhibitors in clinical development in o...

Read more

ORYZON to present new clinical data and corporate updates at international conferences in November and December

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON reports results and corporate update for first half ended June 30, 2021

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

Read more

ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today...

Read more

ORYZON to present new clinical data and corporate updates at international conferences in May and June

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON to participate in upcoming virtual international conferences in March and April

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON to present new clinical data and corporate updates at conferences in February and March

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New advances in cancer viral immunothera...

by Universitat de Barcelona

It has been developed a new strain of vaccinia virus, which can replic...

Photos Stream